Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.
Ioannis ParodisJulius LindblomGuillermo BarturenRafaela Ortega-CastroRicard CerveraJacques-Olivier PersFernanda GenreFalk HiepeMaria GerosaLászló KovácsEllen De LangheSilvia PiantoniGeorg StummvollCarlos VasconcelosBarbara VigoneTorsten Wittenull nullMarta E Alarcón-RiquelmeLorenzo BerettaPublished in: Annals of the rheumatic diseases (2024)
We demonstrated for the first time molecular signalling pathways distinguishing LLDAS/remission from active SLE. LLDAS/remission was associated with reversal of biological processes related to SLE pathogenesis and specific clinical manifestations. DEP clustering by remission better grouped patients compared with LLDAS, substantiating remission as the ultimate treatment goal in SLE; however, the lack of substantial pathway differentiation between the two states justifies LLDAS as an acceptable goal from a biological perspective.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- end stage renal disease
- newly diagnosed
- single cell
- ejection fraction
- rna seq
- gene expression
- single molecule
- patient reported outcomes
- drug induced
- patient reported